Product Description
AVZO-103 is a potential best-in-class BsADC targeting Nectin4 and TROP2. Nectin4 and TROP2 are co-expressed in many solid tumors, including urothelial and breast cancers. AVZO-103 is being evaluated as a potential new approach to overcome resistance to or limitations associated with the existing standard of care, including for patients with locally advanced or metastatic urothelial cancer. (Sourced from: https://avenzotx.com/pipeline-and-science/)
Mechanisms of Action: NECTIN4 Inhibitor, TROP2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: Fast Track - Bladder Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Avenzo Therapeutics, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Transitional Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07193511 |
AVZO-103-1001 | P2 |
Recruiting |
Transitional Cell Carcinoma |
2030-03-01 |
58% |
2025-10-03 |